Atrial Fibrillation (AF)

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. Oxidative stress is now known to play an important role in the pathogenesis and perpetuation of AF. Studies have shown that people with atrial fibrillation have significantly depleted glutathione levels.
 
Glutathione precursors have been found to markedly reduce the incidence of paroxysmal atrial fibrillation and may also attenuate the associated electrophysiological remodelling. (Liu et al, Antioxidant Therapies in the Prevention and Treatment of Atrial Fibrillation, February 2013)

"Deficiency in systemic glutathione in cardiac patients occurs well before the drop in cardiac tissue glutathione. Several studies provide evidence for a close relationship between blood glutathione decrease and the pathogenesis of different inflammatory chronic diseases. In the cardiac myocyte, glutathione deficiency fuels a vicious TNF / sTNFR1/ oxidative stress / neutral sphingomyelinase/ apoptosis cycle. Accordingly, early deficiency in systemic glutathione is likely to contribute to the progression of the cardiac disease.

...In agreement with the previous observation made by Carnes et al, we found a 50% decrease in atrial glutathione content in patients with permanent atrial fibrillation compared to other patients with sinus rhythm, which is also consistent with the decreased incidence of postoperative atrial fibrillation observed after intravenous supplementation with the glutathione precursor, N-acetylcysteine (NAC). Taken together, these results suggest that glutathione deficiency impinges on the whole damaged heart. They also suggest that glutathione supplementation may improve cardiac cell preservation in cardiac diseases, and be a complement to contemporary treatments." ~ Damy et al, Glutathione Deficiency in Cardiac Patients, PLoS ONE, March 2009

Glutathione is able to neutralise oxidative stress and is also a powerful natural anti-inflammatory. Studies have shown that optimised glutathione levels are beneficial for cardiovascular health, but in practice it can be difficult to effectively increase systemic glutathione levels, as glutathione (GSH) is a fragile molecule that is quickly broken down in the digestive system if taken by mouth. Glutathione must be synthesised within the cell because it cannot be transported into cells.

The glutathione prodrug RiboCeine™ delivers the essential precursor nutrients (ribose and cysteine) to the cell where they can then be turned into glutathione and cellular energy in the form of ATP. RiboCeine™ has received extensive scientific validation in published peer-reviewed studies and has been shown to increase intracellular glutathione far more effectively than the synthetic glutathione precursor NAC (n-acetyl cysteine).

Advanced nutritional supplement Cellgevity™ contains RiboCeine™ in combination with a selection of synergistic antioxidant and flavonoid ingredients, including resveratrol, quercetin, alpha lipoic acid, selenomethionine and curcumin. Cellgevity has been clinically proven to effectively raise cellular glutathione levels.




Facebook Comments: